Alpha Cognition’s Resale Statement Goes Live
Company Announcements

Alpha Cognition’s Resale Statement Goes Live

Alpha Cognition Inc (TSE:ACOG) has released an update.

Alpha Cognition Inc., a biopharmaceutical firm focusing on neurodegenerative disorders, has had its resale registration statement declared effective by the SEC. This allows for the resale of common shares from private placements completed in 2023 and early 2024, turning the company into a reporting issuer in the US. However, Alpha Cognition will not be selling any new securities or receiving proceeds from the sales under this registration.

For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Secures Patent for Alzheimer’s Drug ZUNVEYL
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Inc. Adjusts Funding Strategy Amid Market Challenges
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition’s New Alzheimer’s Drug Wins FDA Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App